This review is the first to provide a comprehensive overview of the latest advancements in metastatic brain tumors. Professor Rongrong Zhou and colleagues not only highlight preclinical progress, such as the development of model systems and exploration of underlying mechanisms, but also offer a thorough summary of the evolution of various clinical therapies and cutting-edge treatments. Additionally, the integration of multi-omics technologies in the modern era is depicted, shedding new light on the intricate landscape of brain metastasis and unveiling its mystery.

A multicenter phase II trial has demonstrated that a combination of pyrotinib and fulvestrant offers significant antitumor activity and acceptable safety for hormone receptor-positive (HR+)/HER2-positive metastatic breast cancer patients who have developed resistance to trastuzumab. The study revealed a median progression-free survival (PFS) of 18.2 months and a disease control rate (DCR) of 97.5%, highlighting a novel therapeutic strategy for this challenging patient population.A multicenter phase II trial has demonstrated that a combination of pyrotinib and fulvestrant offers significant antitumor activity and acceptable safety for hormone receptor-positive (HR+)/HER2-positive metastatic breast cancer patients who have developed resistance to trastuzumab. The study revealed a median progression-free survival (PFS) of 18.2 months and a disease control rate (DCR) of 97.5%, highlighting a novel therapeutic strategy for this challenging patient population.

Researchers at Tel Aviv University have developed a new platform using polymeric nanoparticles to deliver drug pairs to specific cancer types, including skin cancer and breast cancer. The researchers explain that having both drugs arrive at the tumor site together significantly amplifies their therapeutic effects and safety profiles.

Led by Texas A&M University graduate students Samere Zade of the biomedical engineering department and Ting-Ching Wang of the chemical engineering department, an article released by the Lele Lab has uncovered new details about the mechanism behind cancer progression. Published in Nature Communications, the article explores the influence the mechanical stiffening of the tumor cell’s environment may have on the structure and function of the nucleus.